AQR Capital Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-391,860
| Closed | -$717K | – | 2225 |
|
|
2022
Q2 | $717K | Buy |
+391,860
| New | +$717K | ﹤0.01% | 1545 |
|
|
2021
Q4 | – | Sell |
-17,486
| Closed | -$89K | – | 2213 |
|
|
2021
Q3 | $89K | Sell |
17,486
-116,799
| -87% | -$594K | ﹤0.01% | 2206 |
|
|
2021
Q2 | $850K | Buy |
134,285
+33,277
| +33% | +$211K | ﹤0.01% | 1656 |
|
|
2021
Q1 | $781K | Sell |
101,008
-22,921
| -18% | -$177K | ﹤0.01% | 1660 |
|
|
2020
Q4 | $812K | Buy |
123,929
+1,937
| +2% | +$12.7K | ﹤0.01% | 1594 |
|
|
2020
Q3 | $811K | Sell |
121,992
-68,333
| -36% | -$454K | ﹤0.01% | 1524 |
|
|
2020
Q2 | $1.59M | Buy |
190,325
+49,986
| +36% | +$416K | ﹤0.01% | 1270 |
|
|
2020
Q1 | $1.08M | Buy |
140,339
+8,781
| +7% | +$67.3K | ﹤0.01% | 1311 |
|
|
2019
Q4 | $1.09M | Buy |
131,558
+76,900
| +141% | +$639K | ﹤0.01% | 1481 |
|
|
2019
Q3 | $403K | Buy |
54,658
+16,201
| +42% | +$119K | ﹤0.01% | 1820 |
|
|
2019
Q2 | $431K | Buy |
38,457
+16,356
| +74% | +$183K | ﹤0.01% | 1774 |
|
|
2019
Q1 | $238K | Buy |
22,101
+3,482
| +19% | +$37.5K | ﹤0.01% | 2033 |
|
|
2018
Q4 | $281K | Sell |
18,619
-13,871
| -43% | -$209K | ﹤0.01% | 1984 |
|
|
2018
Q3 | $601K | Sell |
32,490
-8,723
| -21% | -$161K | ﹤0.01% | 1888 |
|
|
2018
Q2 | $942K | Sell |
41,213
-4,499
| -10% | -$103K | ﹤0.01% | 1744 |
|
|
2018
Q1 | $1.3M | Sell |
45,712
-49,675
| -52% | -$1.41M | ﹤0.01% | 1562 |
|
|
2017
Q4 | $2.01M | Buy |
95,387
+42,751
| +81% | +$903K | ﹤0.01% | 1379 |
|
|
2017
Q3 | $956K | Buy |
52,636
+38,925
| +284% | +$707K | ﹤0.01% | 1697 |
|
|
2017
Q2 | $213K | Buy |
+13,711
| New | +$213K | ﹤0.01% | 2114 |
|